A Study to Evaluate the Efficacy and Safety of UI022/UI023

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.

Also called NCT07600385

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 260 participants (enrolled count) (from the registry)
Sponsor
Korea United Pharm. Inc. (from the registry)
Registry
  • NCT NCT07600385
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07600385. Randomized; double masking; primary purpose treatment. Start 2019-03-12 (actual); primary completion 2022-05-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of UI022/UI023
Condition
Peripheral Arterial Disease
Intervention (Drug)
UI022 or UI023 and co-administration of matching placebo
Intervention (Drug)
UIC201604 or UIC201801 and co-administration of matching placebo
Lead sponsor
Korea United Pharm. Inc. (class: industry)

Record details

Record id
cardio:ct-nct07600385
Content hash
5fd5f08c3dafd217239fae062faaadbd35a8c48871e4f6583def0c313b5ae0c2